Is Eli Lilly Stock Outperforming the Dow?

Eli Lilly and Company, a pharmaceutical giant based in Indianapolis, has shown impressive growth in recent years, outperforming the Dow Jones Industrial Average. With a market capitalization of $1.1 trillion, LLY is classified as a mega-cap stock, reflecting its significant influence in the drug manufacturing sector. Over the past 52 weeks, LLY has surged 60.2%, more than doubling the Dow's gain of 17.6%.

Even more notably, LLY has consistently outperformed its peer, Johnson & Johnson, which has only grown 50.3% over the same period. The stock's bullish trajectory was further bolstered by recent acquisitions and collaborations aimed at bolstering its pipeline with high-potential assets, while also protecting its near-term margins.

Analysts are highly optimistic about LLY, with a consensus rating of "Strong Buy" and a mean price target of $1,335.32, suggesting a 13.5% upside from current levels.